Overview

Our AFP TCR therapeutic is targeted to a peptide associated with hepatocellular carcinoma. The US Food and Drug Administration accepted our investigational new drug (IND) application for our AFP T-cell therapy in April 2016 and the IND is now active. The safety and anti-tumor activity of our AFP T-cell therapy in patients with locally advanced or metastatic hepatocellular carcinoma will be evaluated in a Phase I study and site selection activities are under way.

Pipeline

Candidate Indication Partner Development Stage
Research Pre-IND Phase 1/2
AFP TCR Hepatocellular Cancer Wholly Owned
Research Phase complete
Pre-IND Phase in progress
Phase 1/2 Phase not started
Cohort 1: IND open
Research Phase complete
Pre-IND Phase in progress
Phase 1/2 Phase not started